Understanding the Depressed Brain: What’s Really Happening Inside

Most people who have struggled with depression have heard the serotonin explanation: your brain isn’t making enough of it, so an antidepressant helps restore the balance. That explanation is not false, but it accounts for only part of what a depressed brain is actually doing, and for a significant portion of patients, it turns out to be the less important part. At Soft Reboot Wellness in Menlo Park, we spend a lot of time with patients who have lived this gap firsthand: people who tried the serotonin approach, sometimes for years, and found it didn’t close.

The Glutamate System: The Story Standard Care Underemphasizes

When researchers began looking seriously at why antidepressants work for some people and not others, attention shifted toward a neurotransmitter most patients have never heard of: glutamate. Unlike serotonin, which modulates mood as one signal among many, glutamate is the brain’s primary excitatory neurotransmitter, responsible for the vast majority of signaling between neurons (National Institutes of Health). It is involved in learning, memory, synaptic plasticity, and the brain’s ability to reorganize itself in response to experience.

In a healthy brain, glutamate signaling operates within a careful balance. In a depressed brain, that balance is disrupted, and the consequences ripple outward. The NMDA receptor (N-methyl-D-aspartate receptor), which sits at the center of glutamate signaling and plays a central role in synaptic plasticity, begins to malfunction (National Institutes of Health). Synaptic plasticity is the technical term for the brain’s capacity to strengthen or weaken the connections between neurons depending on how they are being used, the mechanism underlying learning, adaptation, and recovery. When NMDA receptor function falters, the brain loses some of this adaptability, and mood regulation suffers in ways that serotonin-targeting medications do not directly address.

This is not a niche theory. It is increasingly the central explanation for why treatment-resistant depression exists at all, and it is the scientific basis for why ketamine, which works primarily through NMDA receptor blockade, has attracted such serious clinical interest over the past two decades. For a deeper look at the brain changes depression produces, see our post on what depression does to the brain.

What Memory Difficulties Are Telling You

Many people with depression report that their cognition changes alongside their mood. Words come more slowly. Concentration requires effort that used to be effortless. Past memories feel dulled or inaccessible. These are not separate symptoms from the depression. They are part of the same underlying neurobiology (National Institutes of Health).

The hippocampus, a brain structure critical to memory formation and retrieval, is particularly sensitive to the stress hormones elevated in chronic depression. Over time, high cortisol (the primary stress hormone) damages neurons in the hippocampus, contributing to the cognitive symptoms that many patients find as debilitating as the emotional ones. For professionals in Silicon Valley, where cognitive performance is closely tied to professional identity and career functioning, this aspect of depression often carries its own separate weight.

Understanding that these cognitive difficulties have a biological basis, that they are not a character issue or a sign of diminished capability, is something we address directly with patients at Soft Reboot Wellness. The brain changes that depression produces are real, measurable, and in many cases reversible with treatment that targets the right systems.

Why SSRIs Leave a Gap for Some Patients

SSRIs, selective serotonin reuptake inhibitors, work by blocking the reabsorption of serotonin into neurons, keeping more of it active in the space between cells. They are a genuine first-line treatment option and help many people significantly (National Institutes of Health). But they do not touch the glutamate system. They do not directly address NMDA receptor dysfunction. And they typically require six to eight weeks before any meaningful clinical effect is evident, a timeline that reflects the slow, indirect path through which serotonin changes eventually influence neuroplasticity. For a detailed comparison of how ketamine and SSRIs differ mechanically, see our post on ketamine versus SSRI treatment.

For a patient whose depression is primarily driven by glutamate dysregulation and reduced synaptic plasticity, this means that even a well-chosen, well-tolerated SSRI at the right dose may simply be pulling a lever that isn’t connected to the problem. This is not a failure of the medication. It is a mismatch between mechanism and condition.

When patients come to us having tried multiple antidepressants without adequate relief, the working hypothesis we start with is not that the next SSRI or SNRI will be the answer. It is that the serotonin system may not be the primary driver of their depression, and that a treatment targeting glutamate and neuroplasticity directly may be what’s been missing.

What the Depressed Brain Needs to Recover

Recovery from depression, real recovery, not just symptom suppression, requires the brain to rebuild the neural architecture that chronic depression has degraded. This means restoring BDNF (brain-derived neurotrophic factor) levels to support neuron health, repairing synaptic connections in mood-regulating circuits, and re-establishing the kind of glutamate system balance that allows the brain to adapt, learn, and regulate emotion effectively.

Treatment that promotes this kind of recovery works differently than treatment that simply modulates neurotransmitter availability. Ketamine, administered as an IV infusion, blocks NMDA receptors transiently and triggers a downstream release of glutamate in a pattern that activates neuroplasticity pathways, essentially jumpstarting the repair process (National Institutes of Health). The effect is fast by psychiatric standards: many patients report meaningful mood changes within hours of their first infusion, with the neuroplastic effects persisting and consolidating in the days that follow.

At Soft Reboot Wellness, a standard ketamine induction series involves four to six IV ketamine infusions over four to six weeks. Dr. Sara Herman, a Harvard-trained anesthesiologist with Advanced Certificate training in psychedelic-assisted therapy, personally provides and monitors all infusion sessions. We track mood progress through the Osmind platform so you and our team can assess your response objectively rather than relying on memory alone. For patients who want to build on the neuroplastic window the infusions open, our ketamine-assisted psychotherapy (KAP) program adds structured preparation and integration work with a certified psychedelic integration coach.

The Scheduling and Cost Questions

We know that for many patients considering ketamine therapy, the questions are not only neurological. They are practical. How disruptive is this to a work schedule? What does it cost, and will insurance cover any of it?

On scheduling: a ketamine infusion session does not require days of recovery. Most patients return to regular activities the following day, and we offer appointment times designed to accommodate demanding professional schedules. To get started, call or email us directly, we send you an intake packet, Dr. Herman reviews it, and then determines whether to schedule a consultation.

On cost: IV ketamine for mental health is considered an off-label treatment, and insurance coverage is inconsistent. We recommend calling us at 650-419-3330 or contacting us at hello@softrebootwellness.com to discuss costs before your consultation so that financial clarity is part of the decision-making process, not an afterthought. Results vary by individual, and we encourage everyone to discuss their options with their healthcare provider before starting.

Frequently Asked Questions

If my depression involves glutamate, why didn’t my doctor tell me that? Glutamate’s role in depression has become much clearer in the research over the past two decades, but it hasn’t yet shifted mainstream prescribing practice in the same way serotonin science did. Most primary care providers and psychiatrists are appropriately focused on first-line serotonin-targeting medications, which help many patients. The glutamate conversation typically becomes relevant when those first-line options have not produced adequate results. We are happy to discuss where your history fits into this picture during a consultation.

Can the cognitive symptoms of depression, the brain fog and memory issues, improve with treatment? Research suggests they can, particularly when treatment addresses the underlying neurobiological disruption rather than just surface symptoms (National Institutes of Health). The hippocampal changes associated with chronic depression are not necessarily permanent, and treatments that promote neuroplasticity, including ketamine, may support cognitive recovery alongside mood improvement. Results vary significantly between individuals.

Is the glutamate system involved in anxiety as well? Yes. The glutamate and NMDA receptor systems are implicated in anxiety disorders as well as depression, which may help explain why patients with comorbid anxiety and depression sometimes see both improve with ketamine treatment. We treat anxiety at Soft Reboot Wellness and assess the full scope of a patient’s condition during the consultation process.

What makes Soft Reboot different from other ketamine clinics in the Bay Area? Our clinical foundation is built on Dr. Herman’s background as a Harvard-trained anesthesiologist with psychedelic medicine credentials and IFS therapy training, a combination that shapes both the safety standards and the integration approach of our practice. We also work actively with patients’ existing care teams, use structured mood tracking, and offer KAP for patients who want the infusion experience embedded in a broader therapeutic framework. We think the neuroplastic window ketamine opens is best used, not just survived.

Key Takeaways

• The depressed brain shows measurable disruptions in glutamate signaling, NMDA receptor function, and neuroplasticity, changes that serotonin-targeting medications do not directly address.
• Cognitive symptoms like brain fog and memory difficulties are part of the same underlying neurobiology as mood symptoms, not separate complaints.
• SSRIs work well for many patients, but do not directly treat glutamate dysregulation, leaving a gap that IV ketamine therapy is specifically designed to fill.
• IV ketamine at Soft Reboot Wellness in Menlo Park targets the NMDA receptor system, promoting rapid neuroplasticity and BDNF restoration.
• Results vary by individual; treatment is initiated following a thorough medical and psychiatric consultation.

Depression’s grip on the brain is real, but so is the brain’s capacity to change when it gets the right input. If you have been trying to feel better using tools that may not be reaching the right systems, we would like to talk with you about what else may be possible. Reach us at 650-419-3330 or email hello@softrebootwellness.com to start the conversation.

References

1. National Institutes of Health. The glutamate neurotransmitter system is the brain’s primary excitatory system and a key pathway through which ketamine produces its therapeutic effects. https://www.ncbi.nlm.nih.gov/books/NBK62187/
2. National Institutes of Health. NMDA receptors play a central role in synaptic plasticity and are the primary target of ketamine’s antidepressant action. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965111/
3. National Institutes of Health. Research shows depression can impair memory and cognitive function, which may be improved with effective treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC5835184/
4. National Institutes of Health. Research documents the efficacy and limitations of SSRIs as a first-line treatment for depression and anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
5. National Institutes of Health. Ketamine promotes neuroplasticity, the brain’s ability to form new neural connections, which may explain its rapid and sustained antidepressant effects. https://pmc.ncbi.nlm.nih.gov/articles/PMC8190578/

Medical Disclaimer: The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression and related conditions, including IV ketamine therapy, should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.